We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 12 januari 2018

Nature Reviews Endocrinology - Table of Contents alert Volume 14 Issue 2

If you are unable to see the message below, click here to view.
Nature Reviews Endocrinology

Do you have a career question? 

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today!
February 2018 Volume 14 Number 2
Nature Reviews Endocrinology cover
2016 2-year Impact Factor 18.318
Journal Metrics 2-year Median 13
In this issue
Research Highlights
Year in Review
Also this month
 Featured article:
Targeting thermogenesis in brown fat and muscle to treat obesity and metabolic disease
Matthias J. Betz & Sven Enerb├Ąck

Recommend to library

Gut microbiota: Fibre restores healthy gut microbiota
Published online: 29 December 2017
p63 | doi:10.1038/nrendo.2017.182


Diabetes: ANGPTL8 as an early predictor of gestational diabetes mellitus
Published online: 08 December 2017
p64 | doi:10.1038/nrendo.2017.167


Thyroid function: Thyroid hormone therapy resolves pulmonary fibrosis in mice
Published online: 22 December 2017
p64 | doi:10.1038/nrendo.2017.172


Obesity: Ankyrin-B in susceptibility to obesity
Published online: 01 December 2017
p65 | doi:10.1038/nrendo.2017.163


Obesity: Sex differences in insulin resistance
Published online: 08 December 2017
p65 | doi:10.1038/nrendo.2017.168


Technology watch: AI can diagnose diabetic retinopathy
Published online: 22 December 2017
p65 | doi:10.1038/nrendo.2017.177


Reproductive endocrinology: Restoring ovarian function
Published online: 15 December 2017
p66 | doi:10.1038/nrendo.2017.171


Therapy: Achieving T2DM remission in primary care
Published online: 22 December 2017
p66 | doi:10.1038/nrendo.2017.176



Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials
Rury R. Holman

Published online: 05 January 2018
p67 | doi:10.1038/nrendo.2017.179

The risk of death from cardiovascular causes in people with type 2 diabetes mellitus remains around twice that in the general population, with heart failure a common event. In 2017, results from cardiovascular outcome trials in people with diabetes mellitus showed that some drugs have dual utility — reducing cardiovascular risk and improving glycaemic control.
Full Text | PDF

Nutraceuticals in 2017: Nutraceuticals in endocrine disorders
Amanda J. Berberich & Robert A. Hegele

Published online: 22 December 2017
p68 | doi:10.1038/nrendo.2017.169

Nutraceuticals are gaining legitimacy and their potential clinical role is expanding. Data from 2017 provides evidence for their possible use in type 2 diabetes mellitus, the metabolic syndrome, obesity, dyslipidaemia and osteoporosis. Ongoing high-quality research in this area might justify future selective implementation of nutraceuticals into general health practice.
Full Text | PDF

Growth and growth disorders in 2017: Genetic and epigenetic regulation of childhood growth
Ola Nilsson

Published online: 29 December 2017
p70 | doi:10.1038/nrendo.2017.178

Studies of rare growth disorders taken together with large-scale genetic studies of adult height variability have uncovered a large genetic network regulating childhood growth. Advances in technology and experimental model systems will help decipher the molecular mechanisms of this complex network and lead to novel treatment approaches for growth disorders.
Full Text | PDF

Immunometabolism in 2017: Metabolism and the inflammasome in health and ageing
Thomas Mandrup-Poulsen

Published online: 29 December 2017
p72 | doi:10.1038/nrendo.2017.175

Extracellular danger-associated molecular patterns signal to NOD-like receptors, but the exact signalling pathways remain unclear. The inflammasomes, a subgroup of these receptors, translate danger signals into inflammatory responses by maturing IL-1 and IL-18. In 2017, researchers reported novel functions of the mutual interaction between metabolism and the inflammasomes in health and disease.
Full Text | PDF

The artificial pancreas in 2017: The year of transition from research to clinical practice
Boris Kovatchev

Published online: 22 December 2017
p74 | doi:10.1038/nrendo.2017.170

The artificial pancreas — the automated closed-loop control of diabetes mellitus — made its first outpatient strides in 2011. In 2017, the results of long-term clinical trials on the artificial pancreas were published, the first hybrid commercial artificial pancreas system was approved and the artificial pancreas was tested under increasingly demanding conditions. Thus, artificial pancreas technology is here to stay.
Full Text | PDF

Targeting thermogenesis in brown fat and muscle to treat obesity and metabolic disease
Matthias J. Betz & Sven Enerback

Published online: 23 October 2017
p77 | doi:10.1038/nrendo.2017.132

Targeting thermogenesis in brown fat and skeletal muscle to expend energy and reduce fat mass is a promising therapeutic strategy for treating obesity and related metabolic diseases. Here, Betz and Enerback discuss the different molecular pathways regulating thermogenesis in these organs and discuss how they can be therapeutically exploited.
Abstract | Full Text | PDF

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Yan Zheng, Sylvia H. Ley & Frank B. Hu

Published online: 08 December 2017
p88 | doi:10.1038/nrendo.2017.151

The global epidemic of type 2 diabetes mellitus (T2DM) and its complications is a major threat to public health. This Review provides an updated view of the global epidemiology of T2DM and the dietary, lifestyle and other risk factors for T2DM and its complications.
Abstract | Full Text | PDF

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Giovanni Targher, Amedeo Lonardo & Christopher D. Byrne

Published online: 29 December 2017
p99 | doi:10.1038/nrendo.2017.173

This Review focuses on the adverse effect of nonalcoholic fatty liver disease (NAFLD) on the risk of chronic vascular complications of diabetes mellitus. The putative pathophysiological mechanisms by which NAFLD might contribute to the development and progression of chronic vascular complications of diabetes mellitus are also discussed, and the principles of NAFLD treatment are critically evaluated.
Abstract | Full Text | PDF | Supplementary information

Primary hyperparathyroidism
Marcella D. Walker & Shonni J. Silverberg

Published online: 08 September 2017
p115 | doi:10.1038/nrendo.2017.104

Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by hypercalcaemia and elevated or inappropriately normal serum levels of parathyroid hormone. Here, Walker and Silverberg review the pathogenesis, diagnosis and management of PHPT, focusing on recent advances in the field.
Abstract | Full Text | PDF

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
Nature Reviews Endocrinology was previously published as Nature Clinical Practice Endocrinology & Metabolism.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature